Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination

Vaccine

Volumn 32, Issue 6, 2014, Pages 645-650

  Schink, Tania ^a   Holstiege, Jakob ^a,c   Kowalzik, Frank ^b   Zepp, Fred ^b   Garbe, Edeltraut ^a  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Febrile convulsion; First dose; MMR; MMRV; Vaccination

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG;

ARTICLE; ATTRIBUTABLE RISK; COHORT ANALYSIS; DATA BASE; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; HEALTH INSURANCE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNIZATION; LICENSING; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VACCINATION;

FEBRILE CONVULSION; FIRST DOSE; MMR; MMRV; VACCINATION;

CHICKENPOX VACCINE; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GERMANY; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; SEIZURES, FEBRILE; VACCINATION; VACCINES, COMBINED;

EID: 84893005044     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.011     Document Type: Article

References (19)

1. CDC Notice to readers: licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR 2005, 54(47):1212-1214.
2. Jacobsen S.J., Ackerson B.K., Sy L.S., Tran T.N., Jones T.L., Yao J.F., et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009, 27(34):4656-4661.
3. Czajka H., Schuster V., Zepp F., Esposito S., Douha M., Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009, 27(47):6504-6511.
4. Rumke H.C., Loch H.P., Hoppenbrouwers K., Vandermeulen C., Malfroot A., Helm K., et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 2011, 29(22):3842-3849.
5. Shinefield H., Black S., Digilio L., Reisinger K., Blatter M., Gress J.O., et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005, 24(8):665-669.
6. Klein N.P., Fireman B., Yih W.K., Lewis E., Kulldorff M., Ray P., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126(1):e1-e8.
7. Kuter B.J., Brown M.L., Hartzel J., Williams W.R., Eves K.A., Black S., et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccine 2006, 2(5):205-214.
8. Pigeot I., Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 2008, 17(3):215-223.
9. Schink T., Garbe E. Representativity of dispensations of non-steroidal anti-inflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2010, 19:S294.
10. Schink T., Garbe E. Assessment of the representativity of in-patient hospital diagnoses in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2010, 19:S178-S179.
11. InEK gGmbH.Deutsche Kodierrichtlinien 2007 Allgemeine und spezielle Kodierrichtlinien für die Verschlüsselung von Krankheiten und Prozeduren [German Coding Guidelines 2007. General and specific coding guidelines for coding of diseases and procedures] 2006, 163. Deutscher Ärzte-Verlag, Köln.
12. Rothman K.J., Greenland S., Lash T.L. Design strategies to improve study accuracy. Modern epidemiology 2008, 168-182. Lippincott, Williams & Wilkins, Philadelphia. 3rd ed.
13. GlaxoSmithKline. Integrated Summary Output (ISO) on febrile convulsions 2011, Internet 01.04.11 [cited 24.09.11]; available from: URL: http://www.gsk-clinicalstudyregister.com.
14. Nolan T., McIntyre P., Roberton D., Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002, 21(3-4):281-289.
15. Verburgh M.E., Bruijnzeels M.A., van der Wouden J.C., van Suijlekom-Smit L.W., van der valden J., Hoes A.W., et al. Incidence of febrile seizures in The Netherlands. Neuroepidemiology 1992, 11(4-6):169-172.
16. Muschenborn-Koglin S., Weiss M., Reinhardt D. [Infants and young children with fever of unknown origin. Systematic procedure based on a diagnosis-therapy diagram]. MMW Fortschr Med 1999, 141(37):26-29.
17. Rothman K.J., Greenland S., Lash T.L. Validity in epidemiologic studies. Modern epidemiology 2008, 128-147. Lippincott, Williams & Wilkins, Philadelphia. 3rd ed.
18. Poethko-Muller C., Kuhnert R., Schlaud M. Durchimpfung und Determinanten des Impfstatus in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007, 50(5-6):851-862.
19. Poggensee G., Reuss A., Reiter S., Siedler A. Überblick und Bewertung der verfügbaren Datenquellen zur Inzidenz impfpräventabler Krankheiten, zum Durchimpfungsgrad und zum Immunstatus. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009, 52(11):1019-1028.